Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.55 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3444339 | 1.00 | BHMT (0.55) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL5016344 | 0.87 | BHMT (0.56) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL9654172 | 0.87 | BHMT (0.56) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1411236 | 0.84 | SLC1A1 (0.52) | BHMTGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL130831 | 0.84 | SLC1A1 (0.52) | BHMTGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL172526 | 0.84 | SLC1A1 (0.52) | BHMTGRM8GRM6GRIN2DGRIN3B | |
| Water SCHEMBL21597885 | 0.83 | SLC1A1 (0.50) | BHMTGRM8GRM6GRIN2DGRIN3B | |
| Water SCHEMBL21597884 | 0.83 | SLC1A1 (0.50) | BHMTGRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL2124738 | 0.83 | SLC1A1 (0.50) | BHMTGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL28096239 | 0.83 | SLC1A1 (0.50) | BHMTGRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816489-B2 | Methods for making intermediates and oxytocin analogues | FERRING B.V. (NL) | 2010-10-19 | — | — | US | disclosed |
| US-20080177035-A1 | METHODS FOR MAKING INTERMEDIATES AND OXYTOCIN ANALOGUES | FERRING B.V. (NL) | 2008-07-24 | — | — | US | disclosed |
| US-7304181-B2 | Methods for making intermediates and oxytocin analogues | FERRING BV (NL) | 2007-12-04 | — | — | US | disclosed |
| EP-1480998-B1 | INTERMEDIATES AND METHODS FOR MAKING HEPTAPEPTIDE OXYTOCIN ANALOGUES | FERRING BV (NL) | 2006-11-22 | — | — | EP | disclosed |
| US-20060247157-A1 | METHODS FOR MAKING INTERMEDIATES AND OXYTOCIN ANALOGUES | FERRING BV (NL) | 2006-11-02 | — | — | US | disclosed |
| US-7091314-B2 | Intermediates and methods for making heptapeptide oxytocin analogues | FERRING BV (NL) | 2006-08-15 | — | — | US | disclosed |
| EP-1480998-A4 | INTERMEDIATES AND METHODS FOR MAKING HEPTAPEPTIDE OXYTOCIN ANALOGUES | FERRING BV (NL) | 2005-06-08 | — | — | EP | disclosed |
| US-20040248776-A1 | Intermediates and methods for making heptapeptide oxytocin analogues | FERRING B.V. (NL) | 2004-12-09 | — | — | US | disclosed |
| EP-1480998-A1 | INTERMEDIATES AND METHODS FOR MAKING HEPTAPEPTIDE OXYTOCIN ANALOGUES | Ferring BV (NL) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072597-A1 | INTERMEDIATES AND METHODS FOR MAKING HEPTAPEPTIDE OXYTOCIN ANALOGUES | FERRING BV (NL) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177035-A1 | METHODS FOR MAKING INTERMEDIATES AND OXYTOCIN ANALOGUES | OXTR, AVPR1A, AVPR1B | BHMT 1836/4885BHMT2 1352/4885NOS2 502/4885 |
| US-20060247157-A1 | METHODS FOR MAKING INTERMEDIATES AND OXYTOCIN ANALOGUES | OXTR, AVPR1A, AVPR1B | BHMT 1836/4885BHMT2 1352/4885NOS2 502/4885 |
| US-20040248776-A1 | Intermediates and methods for making heptapeptide oxytocin analogues | OXTR, AVPR1A, AVPR1B | BHMT 1609/4885BHMT2 1087/4885NOS2 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.